All In Biotech

Drug Trial Radar · NCT06038396

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC118 in Combination with Toripalimab / RC148 for Patients with Claudin 18.2-Positive, Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

48

Planned (sponsor's estimate)

Start

Aug 3, 2023

Primary completion

Feb 28, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, multi-center, dose escalation and expansion phase I/II study. The Phase I study will explore the tolerability and safety of RC118 in combination with Toripalimab for the treatment of patients with Claudin 18.2-positive, locally advanced unresectable or metastatic malignant solid tumors, and to establish the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); The Phase II study will evaluate the efficacy and safety of RC118 in combination with Toripalimab or RC148 in patients with locally advanced or metastatic Gastric cancer/Gastro-esophageal junction cancer.

Conditions

  • Advanced Solid Tumor

Interventions

  • RC118Drug

    Dose A or dose B, Q2W

  • ToripalimabDrug

    Fixed dose, Q3W

  • RC148Drug

    Fixed dose, Q3W Other Names: RC148 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase1: Dose limiting toxicity (DLT)Time frame: The first 3 weeks (21 days) after the start of dosing at each dose level
  2. Phase1/2: Adverse events (AEs)Time frame: [Time Frame: 15 months]
  3. Phase1: Maximum tolerated dose(MTD)Time frame: up to 12 months
  4. Phase1: Recommended Phase 2 Dose (RP2D)Time frame: up to 12 months
  5. Phase 2: Objective response rate (ORR)Time frame: 15 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Fudan University

    Shanghai, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China · Recruiting

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Nanyang Central Hospital

    Nanyang, Henan, China · Recruiting

  • Xinyang Central Hospital

    Xinyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Shandong, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Changzhi People's Hospital

    Changzhi, Shanxi, China · Recruiting

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The Second People's Hospital of Neijiang

    Neijiang, Sichuan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.